Certified by Founder Lodge
The Column Group
United States - San Francisco, CA
INVESTOR
1 Disclosed Funding Rounds $160,000,000
7 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their uniqu
| Company | Date | Round | Raised |
|---|---|---|---|
Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
Tr1X |
January, 19 ,2024 | Series A | $75,000,000 |
Kenai Therapeutics |
March, 01 ,2024 | Series A | $28,000,000 |
A2 Biotherapeutics, Inc. |
January, 10 ,2025 | Series C | $80,000,000 |
Nilo Therapeutics |
October, 10 ,2025 | Series A | $101,000,000 |
Carmot Therapeutics, Inc.
Atavistik Bio
Remix Therapeutics
Tr1X
Kenai Therapeutics
A2 Biotherapeutics, Inc.
Nilo Therapeutics
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Allos | $5,000,000 | (Jan 14, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)
JetZero | $175,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)